| Rank |
Status |
Study |
| 1 |
Unknown †
|
Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers
| Condition: |
Healthy Male and Female Volunteers |
| Interventions: |
Drug: Furosemide; Drug: aminohippurate sodium |
| Outcome Measures: |
pharmacokinetic parameter of Furosemide (AUC-24); pharmacodynamic parameter of Furosemide (Sodium excretion in the urine); pharmacogenetic parameters; pharmacokinetic of aminohippuric acid; other pharmacokinetic parameter of Furosemide; other pharmacodynamic parameter of Furosemide |
|
| 2 |
Not yet recruiting
|
The Use of Furosemide in Patients on Dialysis
| Condition: |
End Stage Renal Disease |
| Interventions: |
Drug: Withdrawal of Furosemide; Drug: Furosemide administration |
| Outcome Measures: |
24 hour urine sodium and water excretion; Interdialytic weight gain |
|
| 3 |
Recruiting
|
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure
| Condition: |
Acute Decompensated Heart Failure |
| Interventions: |
Drug: Intravenous Bolus Furosemide and Oral Metolazone; Drug: Intravenous Continuous Infusion Furosemide |
| Outcome Measures: |
Daily net fluid output; Patient Global Assessment Scale; Daily urine output (mL urine out per mg Furosemide received); Need for additional or alternative diuretic (crossover) or IV vasoactive therapy (study failure); Death, rehospitalization, and unscheduled visit for HF to an emergency department or outpatient clinic; Critically low potassium (< 3.5 mmol/L) and magnesium (< 1.6 mg/dL) concentrations; Change in blood urea nitrogen or creatinine; Number of hypotensive episodes defined as systolic blood pressure below 85 mmHg or greater than 10 mmHg below baseline (whichever is greater); Total number of times antihypertensive doses are held due to low blood pressure |
|
| 4 |
Unknown †
|
Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial
| Condition: |
Acute Heart Failure |
| Interventions: |
Drug: Furosemide; Drug: low-dose dopamine + low-dose Furosemide |
| Outcome Measures: |
1-year mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).; 60-day mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure). |
|
| 5 |
Unknown †
|
The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Critically Ill Patients
| Condition: |
Intra-Abdominal Hypertension |
| Intervention: |
Drug: Furosemide |
| Outcome Measures: |
intra-abdominal pressure; serum creatinine; need for renal replacement therapy; ICU mortality; acid-base status; hospital and 28d mortality; duration of mechanical ventilation; ICU length of stay; vasopressor dose; fluid balance; SOFA score |
|
| 6 |
Not yet recruiting
|
Inhaled Furosemide & Dyspnea
| Condition: |
Dyspnea |
| Interventions: |
Other: CWS; Drug: Furosemide; Drug: Placebo |
| Outcome Measure: |
Sensory intensity (Borg 0-10 scale) ratings of dyspnea at isotime |
|
| 7 |
Recruiting
|
Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
| Condition: |
Acute Kidney Injury |
| Interventions: |
Drug: Furosemide; Procedure: Peritoneal Dialysis |
| Outcome Measures: |
Fluid Balance; Respiratory Support Administered; NGAL Concentration; Duration of cardiac ICU stay; Duration of hospital stay; All cause mortality; Renal/electrolyte abnormalities; Doses of Potassium Chloride or Arginine Chloride required; B-Natriuretic Peptide |
|
| 8 |
Recruiting
|
Furosemide in Early Acute Kidney Injury
| Condition: |
Acute Renal Failure |
| Interventions: |
Drug: Furosemide; Drug: Normal Saline |
| Outcome Measures: |
Worsening AKI; Fluid balance; Renal replacement therapy (RRT); Renal Recovery; Survival |
|
| 9 |
Unknown †
|
Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
| Condition: |
Obesity-induced Hyperfiltration |
| Intervention: |
Drug: Furosemide, acetazolamide |
| Outcome Measure: |
change in GFR and RPF |
|
| 10 |
Recruiting
|
Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea
| Condition: |
Transient Tachypnoea of the Newborn |
| Interventions: |
Drug: Furosemide; Drug: Saline 0,9% |
| Outcome Measures: |
Reduction of the Silverman-Score; Oxygen supplementation; A need for secondary intubation and mechanical ventilation; body weight; CPAP-time; blood electrolytes (Na+, K+, Ca++, HCO3-, Cl-); blood gas (pH, pCO2,pO2) |
|
| 11 |
Recruiting
|
Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease
| Condition: |
Fluid Overload |
| Interventions: |
Drug: Furosemide; Drug: ethacrynic acid |
| Outcome Measures: |
Mean total urine output production in the first post-operative day; Mean creatinine and NGAL values |
|
| 12 |
Unknown †
|
Using Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates
| Condition: |
Lung Disease |
| Interventions: |
Drug: Furosemide; Drug: Saline |
| Outcome Measures: |
Cardiac chamber volume loading.; Clinical cardio-respiratory stability (heart rate, blood pressure, respiratory rate, oxygen saturation, and oxygen requirement).; Myocardial performance, cardiac input and output and pulmonary hemodynamics (echocardiograph exam).; Changes in electrolyte balance, body weight and urine output. |
|
| 13 |
Not yet recruiting
|
Furosemide Treatment Before Blood Transfusion in Patients With Systolic Dysfunction
| Condition: |
Anemia Treatment Among Patients Suffering From Left Ventricular Systolic Dysfunction |
| Interventions: |
Drug: Furosemide; Drug: placebo normal saline |
| Outcome Measures: |
Diastolic echocardiographic changes following blood transfusion, with or without Furosemide treatment; clinical outcome following blood transfusion, with or without Furosemide treatment |
|
| 14 |
Unknown †
|
Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis
| Conditions: |
Respiratory Failure; Volume Overload; Hypernatremia |
| Interventions: |
Drug: Supplemental metolazone diuresis; Drug: Placebo Comparator: Control-- Furosemide (lasix) only |
| Outcome Measures: |
Fluid balance; Serum sodium; Hyponatremia; Time to extubation; Acute Kidney Injury |
|
| 15 |
Recruiting
|
Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function
| Conditions: |
Chronic Kidney Insufficiency; Hemodialysis Treatment; Diuresis Preserved |
| Intervention: |
Drug: Hydrochlorothiazide and Furosemide |
| Outcome Measures: |
To asses the effect of combined hydrochlorothiazide-Furosemide therapy on weight gain between haemodialysis sessions in patients with RRF; To asses the effect of combined hydrochlorothiazide-Furosemide therapy on dialytic, clinical and analytical variables and use of the antihypertensive treatment |
|
| 16 |
Not yet recruiting
|
The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure
| Condition: |
Heart Failure |
| Interventions: |
Drug: Furosemide; Drug: Torasemide |
| Outcome Measures: |
The influence of therapy on cardiovascular events associated with heart failure (deaths, hospitalisations); The change of dosing of diuretic due to worsening of condition of patient.; The change of NYHA (New York Heart Association) class - worsening or improvement |
|
| 17 |
Unknown †
|
Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure
| Condition: |
Heart Failure |
| Interventions: |
Drug: Conivaptan; Drug: Furosemide; Drug: Conivaptan and Furosemide |
| Outcome Measures: |
renal hemodynamics renal blood flow and glomerular filtration rate; measure plasma neurohormone levels |
|
| 18 |
Unknown †
|
The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission
| Condition: |
Hearing Status |
| Intervention: |
|
| Outcome Measure: |
|
|
| 19 |
Recruiting
|
Aerosol Inhalation Treatment for Dyspnea
| Conditions: |
Healthy; Dyspnea |
| Intervention: |
Drug: Furosemide |
| Outcome Measures: |
Subject rating of Breathing Discomfort (dyspnea); Multidimensional Dyspnea Profile; Urine output |
|
| 20 |
Not yet recruiting
|
A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)
| Conditions: |
Renal Impairment; Heart Failure |
| Interventions: |
Drug: MK-7145 2 mg; Drug: MK-7145 8 mg; Drug: Furosemide; Drug: Torsemide |
| Outcome Measures: |
Change from baseline in first 24hr UNa (Part I); NT-proBNP values at 24 hours post last dose (Part II); Fold change from baseline for serum creatinine (Part I); Area under the concentration-time curve from time zero to 24 hours after dosing (AUC0-24hr) for MK-7145 (Part I); Maximum plasma concentration (Cmax) for MK-7145 (Part I); Trough plasma concentration (Ctrough) for MK-7145 (Part I); Time to Cmax (Tmax) for MK-7145 (Part I); Apparent terminal half-life (t1/2) for MK-7145 (Part I); Serum creatinine measured at 24 hours post last dose (Part II); Area under the concentration-time curve from time zero to 24 hours after dosing (AUC0-24hr) for MK-7145 (Part II); Maximum plasma concentration (Cmax) for MK-7145 (Part II); Trough plasma concentration (Ctrough) for MK-7145 (Part II); Time to Cmax (Tmax) for MK-7145 (Part II); Apparent terminal half-life (t1/2) for MK-7145 (Part II) |
|
